Company: PSTV
Filing Date: 2025-04-11
Form Type: POS AM
Source: 0001193125-25-079109
Chunk: 11

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-11
Form: POS AM
Chunk 11
---
 prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs.

We will bear the out-of-pocket
costs, expenses, and fees incurred in connection with the registration of the shares of common stock to be sold by the selling stockholders pursuant to this prospectus. Other than registration-related expenses, the selling stockholders will bear
their own broker or similar commissions payable with respect to any sales of their shares of common stock and any legal fees or other costs of the selling stockholders related thereto.

4

SELLING STOCKHOLDERS The selling stockholders listed in the table below may from time to time offer and sell up to an aggregate of 3,248,878 shares of common stock offered and issued in the May 2024 PIPE Financing pursuant to this prospectus and the applicable prospectus supplements, which consists of:

| • |     | up to 108,685 shares of common stock; |

| • |     | up to 48,285 shares of common stock issuable upon exercise of Series A Common Stock Warrants; and |

| • |     | up to 3,091,908 shares of common stock issuable upon exercise of Series B Common Stock Warrants. |

The selling stockholders have not had any material relationship with us within the past three years, except for the ownership of our equity or debt securities, and except for the Company Insiders: (i) Marc H. Hedrick, M.D., is our President and Chief Executive Officer, and a member of our Board of Directors (the “Board”), (ii) Andrew Sims is our Chief Financial Officer, (iii) Richard J. Hawkins is Chairman of our Board, (iv) Robert Lenk, Ph.D., is a member of our Board, (v) Greg Petersen is a member of our Board, and (vi) Howard Clowes is a member of our Board. As used in this prospectus, the term “selling stockholders” includes the selling stockholders listed in the table below, together with any additional selling stockholders listed in a subsequent amendment to this prospectus, and their respective donees, pledgees, assignees, transferees or other successors-in-interestselling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer. In accordance with the terms of the Registration Rights Agreement that we entered into with the Purchasers in connection with the